Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392794 | 1.00 | TAAR1 (0.54) | TAAR1POLBGAATRPM8MC4R | |
| SCHEMBL24540254 | 1.00 | TAAR1 (0.54) | TAAR1POLBGAATRPM8MC4R | |
| SCHEMBL2628705 | 0.93 | KMT2A (0.50) | TAAR1TRPM8MEN1KMT2ACYP2C19 | |
| SCHEMBL15131620 | 0.93 | KMT2A (0.50) | TAAR1TRPM8MEN1KMT2ACYP2C19 | |
| SCHEMBL2628712 | 0.89 | TRPM8 (0.50) | TAAR1POLBGAATRPM8MEN1 | |
| SCHEMBL2628617 | 0.89 | TRPM8 (0.49) | TAAR1POLBGAATRPM8MEN1 | |
| SCHEMBL2628667 | 0.89 | TRPM8 (0.50) | TAAR1POLBGAATRPM8MEN1 | |
| SCHEMBL24540522 | 0.89 | TRPM8 (0.50) | TAAR1POLBGAATRPM8MEN1 | |
| SCHEMBL24540473 | 0.89 | TRPM8 (0.49) | TAAR1POLBGAATRPM8MEN1 | |
| SCHEMBL3392306 | 0.89 | TRPM8 (0.49) | TAAR1POLBGAATRPM8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112930176-A | Cyclohexanecarboxamide derivatives for promoting thermogenesis in adipose tissue | 宝洁公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20200138764-A1 | METHODS AND DEVICES FOR ACTIVATING ADIPOSE TISSUE | THE PROCTER & GAMBLE COMPANY | 2020-05-07 | — | — | US | disclosed |
| WO-2017070418-A1 | SYNTHESIS OF CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170057911-A1 | SYNTHESIS OF ARYL CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | PROCTER & GAMBLE (US) | 2017-03-02 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110091531-A1 | Cooling Composition | GIV AUDAN SA (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TAAR1 192/4885POLB 4508/4885GAA 4768/4885 |
| US-20200138764-A1 | METHODS AND DEVICES FOR ACTIVATING ADIPOSE TISSUE | LRBA, FABP4, LIPE | TAAR1 3380/4885POLB 2691/4885GAA 1566/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TAAR1 522/4885POLB 4566/4885GAA 4570/4885 |
| US-20170057911-A1 | SYNTHESIS OF ARYL CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | CUTA, ACMSD, SRM | TAAR1 110/4885POLB 3398/4885GAA 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.